Titan Biotech Limited (BOM:524717)
India · Delayed Price · Currency is INR 1,212.15
+74.25 (6.53%)
At close: Feb 13, 2026
Titan Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 1,925 | 1,565 | 1,641 | 1,440 | 1,235 | 1,422 |
Other Revenue | - | - | - | - | - | 0.04 |
| 1,925 | 1,565 | 1,641 | 1,440 | 1,235 | 1,422 | |
Revenue Growth (YoY) | 19.43% | -4.64% | 13.94% | 16.55% | -13.14% | 79.05% |
Cost of Revenue | 939.44 | 741.94 | 769.36 | 710.43 | 598.28 | 645.68 |
Gross Profit | 985.82 | 822.57 | 871.36 | 729.57 | 637.21 | 776.72 |
Selling, General & Admin | 345.09 | 310.18 | 267.96 | 209.68 | 148.78 | 144.39 |
Other Operating Expenses | 307.56 | 259.6 | 262.02 | 225.04 | 176.6 | 166.14 |
Operating Expenses | 697.36 | 611.47 | 563.29 | 461.52 | 349.08 | 334.8 |
Operating Income | 288.46 | 211.1 | 308.08 | 268.05 | 288.13 | 441.92 |
Interest Expense | -3.94 | -4.4 | -7.96 | -4.5 | -5.99 | -14.79 |
Interest & Investment Income | 5.1 | 5.1 | 0.86 | 0.44 | 1.13 | 0.57 |
Earnings From Equity Investments | 25.45 | 32.61 | 11.9 | 38.19 | - | - |
Currency Exchange Gain (Loss) | - | - | - | - | - | 6.01 |
Other Non Operating Income (Expenses) | 33.97 | 26.25 | 8.69 | 16.68 | 6.44 | -1.49 |
EBT Excluding Unusual Items | 349.04 | 270.65 | 321.56 | 318.87 | 289.71 | 432.21 |
Gain (Loss) on Sale of Investments | 5.63 | 5.63 | 5.63 | 0.49 | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | -0.02 | -0.03 |
Asset Writedown | - | - | - | - | - | -1.88 |
Other Unusual Items | - | - | - | - | - | -3.24 |
Pretax Income | 354.67 | 276.28 | 327.19 | 319.35 | 289.69 | 427.06 |
Income Tax Expense | 82.64 | 60.96 | 78.66 | 70.91 | 72.85 | 110 |
Earnings From Continuing Operations | 272.03 | 215.32 | 248.53 | 248.44 | 216.84 | 317.05 |
Minority Interest in Earnings | - | - | - | - | - | -13.7 |
Net Income | 272.03 | 215.32 | 248.53 | 248.44 | 216.84 | 303.35 |
Net Income to Common | 272.03 | 215.32 | 248.53 | 248.44 | 216.84 | 303.35 |
Net Income Growth | 21.00% | -13.36% | 0.03% | 14.57% | -28.52% | 329.33% |
Shares Outstanding (Basic) | 8 | 8 | 8 | 8 | 8 | 8 |
Shares Outstanding (Diluted) | 8 | 8 | 8 | 8 | 8 | 8 |
Shares Change (YoY) | 0.01% | - | - | - | - | - |
EPS (Basic) | 32.92 | 26.06 | 30.07 | 30.06 | 26.24 | 36.71 |
EPS (Diluted) | 32.92 | 26.06 | 30.07 | 30.06 | 26.24 | 36.71 |
EPS Growth | 20.99% | -13.35% | 0.02% | 14.57% | -28.52% | 329.35% |
Free Cash Flow | - | 107.55 | 16.61 | 84.45 | 157.29 | 160.71 |
Free Cash Flow Per Share | - | 13.01 | 2.01 | 10.22 | 19.03 | 19.45 |
Dividend Per Share | - | 2.000 | 2.000 | 1.800 | 1.500 | 1.500 |
Dividend Growth | - | - | 11.11% | 20.00% | - | 50.00% |
Gross Margin | 51.20% | 52.58% | 53.11% | 50.66% | 51.58% | 54.61% |
Operating Margin | 14.98% | 13.49% | 18.78% | 18.62% | 23.32% | 31.07% |
Profit Margin | 14.13% | 13.76% | 15.15% | 17.25% | 17.55% | 21.33% |
Free Cash Flow Margin | - | 6.87% | 1.01% | 5.86% | 12.73% | 11.30% |
EBITDA | 331.7 | 248 | 336.52 | 289.21 | 307.71 | 460.33 |
EBITDA Margin | 17.23% | 15.85% | 20.51% | 20.08% | 24.91% | 32.36% |
D&A For EBITDA | 43.24 | 36.9 | 28.44 | 21.16 | 19.58 | 18.41 |
EBIT | 288.46 | 211.1 | 308.08 | 268.05 | 288.13 | 441.92 |
EBIT Margin | 14.98% | 13.49% | 18.78% | 18.62% | 23.32% | 31.07% |
Effective Tax Rate | 23.30% | 22.07% | 24.04% | 22.20% | 25.15% | 25.76% |
Revenue as Reported | 1,972 | 1,604 | 1,658 | 1,459 | 1,245 | 1,430 |
Advertising Expenses | - | 40.72 | 26.12 | 26.42 | 5.48 | 2.51 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.